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By the skin of our teeth: potential applications of dental
pulp stem cells to cutaneous disease
Dear Editor,
As the search for novel therapeutics and new treatments
continues in dermatology, a recent discovery in regenerative
medicine has shown increased potential. Dental pulp stem cells
(DPSCs), first isolated by Gronthos & colleagues in 2002, represent a novel adult stem cell population with considerable ability
to proliferate, self-renew, and differentiate into multiple lineages.1 Notably, DPSCs have demonstrated superior growth
potential compared to stem cells harvested from bone marrow.2
Not only do these stem cells have the ability to differentiate into
cell types such as osteoblasts, adipocytes, and chrondrocytes
but their proliferation and differentiation can be induced in vitro
such that a small number of DPSCs can be engineered to produce a large variety of cell types in sufficient amounts for clinical application.3
Currently, the therapeutic potential of DPSCs in humans is
high, with numerous in vivo studies confirming the effects of
DPSCs following transplantation. DPSCs have been used to
treat spinal cord injury, repair infarcted myocardium, modulate
autoimmune conditions, and treat diseases of the pancreas,
liver, and oral cavity.4 However, the clinical applicability of
DPSCs remains limited in humans at this time, with only a
handful of human studies being published in the literature.
These pilot studies have been limited to the treatment of pulpitis
and pulp necrosis, finding the implantation of DPSCs to be safe
and effective albeit in small sample sizes.4–5
One potential dermatological application of DPSCs may be
to treat psoriasis. For years, serious adverse events have been
reported from biologic drugs in psoriatic clinical trials. Meng et al.
sought to provide another means of treatment while avoiding the
use of biologics. Thus, the authors found that the immunomodulatory effects of DPSCs could be amplified with overexpression of
hepatocyte growth factor (HFG) in vivo.6 Topical imiquimod was
used to induce psoriatic symptoms on the backs of mice. An intravenous injection of DPSC suspension was injected, and the skin
lesions were subsequently collected for histological and immunohistochemical analysis. The researchers discovered that HGF-expressed DPSCs downregulated critical pathophysiological
mediators of psoriasis, such as Th1 and Th17 cells, and their
downstream cytokines including IL-17A, IL-17F, IL-23, TNF-a,
and IFN-y. They were also found to upregulate Treg cells and
decrease the production of proinflammatory cytokines such as
cytokeratin 6 and 17. Ultimately, the overexpression of HGF in
DPSCs improved the erythema, scaling, and hyperkeratinization
associated with psoriatic lesions in a mouse model.

DPSCs may also have the potential as an anti-aging treatment. According to Li et al., DPSCs, if co-cultured with skin
fibroblasts, significantly decreased proliferation of the fibroblasts.7 This reduction in dermal fibroblast proliferation appears
to be mediated by effects on the cell cycle. Fibroblasts
decreased in the G1 phase but increased in the S and G2
phases. In addition, fibroblasts co-cultured with DPSCs
expressed increased amounts of pRb and decreased amounts
of p53 and p21.
Although DPSCs were first isolated nearly two decades
ago, the potential therapeutic applications of these stem cells to
cutaneous conditions have not been explored until recently.
The aforementioned studies suggest that DPSCs may
have clinical value in psoriasis treatment and anti-aging via
immunomodulation and alteration of dermal fibroblasts, respectively. Additional studies of DPSCs are needed before human
trials can begin, including additional research to determine the
potential for harmful side effects. Therefore, the use of DPSCs
in dermatological conditions remains in the nascent phases. In
fact, the coming years may reveal additional novel applications
of DPSCs to cutaneous disease.
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